About the Company
We do not have any company description for Cardiff Oncology, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ETCompany ParticipantsKiki Patel - IR, Gilmartin GroupMark ...
Trovagene Announces Changing of Company Name to Cardiff Oncology and ...
About Cardiff Oncology (formerly Trovagene, Inc.) Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in ...
Cardiff Oncology to Report Fourth Quarter 2024 Results and ... - Nasdaq
--Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference ...
Cardiff Oncology Announces the Appointment of Two New Independent ...
SAN DIEGO, June 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for ...
Cardiff Oncology to Present at Upcoming Investor Conferences
Cardiff Oncology Contact: James Levine Chief Financial Officer 858-952-7670 jlevine@cardiffoncology.com Investor Contact: Kiki Patel, PharmD Gilmartin Group 332-895-3225 Kiki@gilmartinir.com ...
Cardiff Oncology Announces New Patent with Claims for the Use of ...
Gilmartin Group 332-895-3225 Kiki@gilmartinir.com Media Contact: Grace Spencer Taft Communications 609-583-1151 grace@taftcommunications.com Source: Cardiff Oncology, Inc. 2024 GlobeNewswire, Inc.
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule ...
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide ...
Cardiff Oncology Contact: James Levine Chief Financial Officer 858-952-7670 jlevine@cardiffoncology.com Investor Contact: Kiki Patel, PharmD Gilmartin Group 332-895-3225 Kiki@gilmartinir.com ...
While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF ...
A look at the shareholders of Cardiff Oncology, Inc. (NASDAQ:CRDF) can tell us which group is most powerful. We can see that retail investors own the lion's share in the company with 49% ownership.
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC ...
Cardiff Oncology announced initial data from the ongoing CRDF-004 trial in December, 2024. Additional clinical data from the trial is expected in 1H of 2025. About Cardiff Oncology, Inc.
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide ...
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage ...
Similar Companies
Loading the latest forecasts...